In a weekly digest usually reserved for hype, Packy McCormick delivers a sobering warning about the very technology designed to entertain us, framing Meta's new AI tool not as a feature, but as a potential existential trap. While the newsletter quickly pivots to a parade of biological miracles—from AI-designed antibodies to the first effective treatment for Huntington's Disease—McCormick's opening serves as a necessary anchor, reminding readers that the tools accelerating our health may also be eroding our attention. This is not just a list of breakthroughs; it is a case study in the dual nature of rapid technological acceleration, where the same computational power that might cure a genetic disease is being deployed to keep us staring at screens until we wither.
The Trap of Infinite Entertainment
McCormick begins by issuing a stark public service announcement against Meta's "Vibes," a new AI generation tool. He draws a chilling parallel to David Foster Wallace's Infinite Jest, describing the technology as an attempt to build "The Entertainment," a fictional substance so absorbing that users literally die from neglecting their lives. The author's choice to invoke this literary dystopia sets a gravity that contrasts sharply with the celebratory tone of the rest of the newsletter. "Like, at a certain point we're gonna have to build up some machinery, inside our guts, to help us deal with this," McCormick writes, quoting the author's own fear that the technology will only become "easier and easier, and more and more convenient, and more and more pleasurable, to be alone with images on a screen, given to us by people who do not love us but want our money." This framing is effective because it shifts the conversation from "is this cool?" to "is this survivable?" It forces the reader to confront the economic incentive behind the technology: engagement at any cost.
The technology is just gonna get better and better and better and better. And it's gonna get easier and easier, and more and more convenient, and more and more pleasurable, to be alone with images on a screen, given to us by people who do not love us but want our money.
Critics might argue that this is alarmist, suggesting that users retain agency to disconnect. However, McCormick's point is that the design of these systems specifically targets the biological mechanisms of addiction, making the choice to disconnect increasingly difficult. The editorial value here lies in refusing to treat the "slop machine" as a neutral tool; it is an active agent in a struggle for human attention.
The Arc of Biological Acceleration
Once the warning is issued, McCormick pivots to the "good news," centering the week's most significant developments on the Arc Institute. He highlights a new model called Germinal, developed in partnership with Stanford, which solves a critical bottleneck in drug discovery. "The ability to design antibodies against any protein of interest has major implications for medicine, biotech, and basic science," writes co-author Santiago Mille, a sentiment McCormick uses to underscore the magnitude of the breakthrough. The core of the argument is that AI is no longer just analyzing existing data; it is generating entirely new biological structures from scratch. By combining AlphaFold Multimer with IgLM, the system creates "de novo" antibodies that bind to targets like the SARS-CoV-2 spike protein with nanomolar affinity, a level of precision previously impossible without years of lab work.
McCormick notes that this approach could compress discovery timelines from years to weeks, a shift that is "incredibly important in combating infectious diseases." This is a compelling narrative of efficiency, but it also hints at a broader democratization of science. If smaller labs can access these computational tools, the monopoly on high-end biotech research may fracture. The author also points to a concurrent breakthrough in gene editing from Patrick Hsu's lab, which uses "bridge recombinase technology" to edit a million DNA bases at once, compared to CRISPR's limit of fewer than 100. "The reason gene editing hasn't transformed human health is that current gene editing technologies like CRISPR are very limited," Hsu tweeted, a claim McCormick presents as a potential inflection point for the entire field.
The reason gene editing hasn't transformed human health is that current gene editing technologies like CRISPR are very limited.
A counterargument worth considering is that computational success does not guarantee clinical safety. Designing a molecule on a computer is one thing; ensuring it behaves predictably in a living human body is another. Yet, the sheer speed of iteration offered by these models suggests that the trial-and-error phase of biology is finally being accelerated to match the pace of software development.
Pausing Time and Rewiring the Brain
The newsletter then explores the concept of "pausing" biology, focusing on Laura Deming's Until Labs, which recently raised $58 million to make cryopreservation a commercial reality. McCormick frames this not as a sci-fi fantasy but as a pragmatic response to the current limitations of organ donation. "Until is building a 'pause button for biology,'" he writes, explaining that the company aims to extend the viability of organs from hours to days or weeks. The technology relies on a simple yet profound insight: "The rate of molecular motion and chemical reactions can be controlled with a single knob: temperature." By cooling tissue to -196°C and rewarming it using custom electromagnetic systems, Until has already demonstrated the recovery of electrical activity in rat brain tissue.
McCormick's commentary on this section is particularly optimistic, noting that even if whole-body cryopreservation takes centuries, the intermediate steps—medical hibernation for terminal patients—could be life-saving within our lifetime. This is followed by a report on Huntington's Disease, where a gene therapy from uniQure slowed disease progression by 75%. "What a miracle, man," McCormick exclaims, capturing the emotional weight of a treatment that turns a "long, slow death sentence" into a manageable condition. The convergence of these stories—cryopreservation, gene therapy, and AI-designed antibodies—paints a picture of a field where the fundamental constraints of biology are being actively dismantled.
The ability to design antibodies against any protein of interest has major implications for medicine, biotech, and basic science.
The Material and Mental Foundations
Beyond biology, McCormick addresses the physical infrastructure of the future and the philosophical underpinnings of intelligence. He highlights Sila Nanotechnologies' opening of the first automotive-scale silicon anode plant in the United States. This move is framed as a strategic shift away from Chinese-dominated supply chains, replacing graphite with silicon-carbon composites that offer 20% better energy density and faster charging. The stakes are high: "By manufacturing domestically at unprecedented scale, Sila is replacing graphite, a critical mineral overwhelmingly sourced from China, with a higher-performing, American-made alternative." The author acknowledges the engineering challenges, noting that early yields may be low and costs high, but the potential to scale to 250 GWh suggests a transformative shift in battery chemistry.
Finally, the piece turns to the nature of the mind itself, citing a conversation between neuroscientist Anil Seth and biologist Michael Levin. McCormick pushes back against the prevailing AI narrative that equates the brain with a computer. "We've forgotten that the idea of the brain as a computer is a metaphor and not the thing itself," Seth argues. The author uses this to critique the assumption that AI will inevitably replicate human consciousness simply because it mimics information processing. Levin offers a counter-perspective, suggesting that computers might access the same "deep, platonic layers of reality" as biology, but through different interfaces. This distinction is crucial for anyone trying to understand the limits of AI; if the brain is not just a processor, then the path to artificial general intelligence is far more complex than simply scaling up current models.
The brain isn't just information processing that can be ported to silicon.
Critics might note that this philosophical debate, while fascinating, does not change the immediate trajectory of AI development. However, McCormick's inclusion of it serves as a necessary check against technological determinism, reminding the reader that the human mind is an emergent, biological phenomenon that may resist simple digitization.
Bottom Line
Packy McCormick's most valuable contribution this week is the juxtaposition of existential risk with biological salvation, forcing the reader to hold two contradictory truths: the tools that threaten our attention are the same ones curing our diseases. The strongest part of the argument is the concrete evidence of acceleration in biotech, particularly the Arc Institute's ability to design molecules and edit genes at unprecedented speeds. The biggest vulnerability lies in the assumption that these technological leaps will translate seamlessly into human health outcomes without unforeseen biological consequences. The reader should watch for the next phase of the Arc Institute's work and the clinical trial results for the Huntington's therapy, as these will determine whether this optimism is grounded in reality or merely a fleeting moment of hype.